AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10919939 — intervention group
Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 91
Study 9285143 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary IgG excretion
Number of subjects: 22
Study 9285143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum albumin and transferrin, high urinary transferrin, beta-microglobulin, and IgG excretion
Number of subjects: 22
Study 8360131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg/day given as a single dose (once-daily)
Number of subjects: 316
Study 8360131 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg/day given in two divided doses at 12 h intervals (twice-daily)
Number of subjects: 316
Study 8360131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (once-daily and twice-daily)
Number of subjects: 316
Study 3526986 — intervention group
Group type: EXPERIMENTAL
Intervention: one inhalation isoetharine mesylate (IM)
Number of subjects: 19
Study 3526986 — intervention group
Group type: EXPERIMENTAL
Intervention: two inhalations isoetharine mesylate (IM)
Number of subjects: 19
Study 3526986 — intervention group
Group type: COMPARATOR
Intervention: one inhalation placebo (P)
Number of subjects: 19
Study 3526986 — intervention group
Group type: COMPARATOR
Intervention: two inhalations placebo (P)
Number of subjects: 19
Study 29803986 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose autologous bone marrow mononuclear cells (200 million cells)
Number of subjects: 0
Study 29803986 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 26837471 — intervention group
Group type: EXPERIMENTAL
Intervention: Human diploid cell‐based inactivated EV71 vaccine
Number of subjects: 12000
Study 24103146 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient informed consent documents
Number of subjects: 9
Study 23678500 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening strategy including body measurements, medical interviews, and seven group educational sessions.
Number of subjects: 0
Study 23678500 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted care management conducted inside schools.
Number of subjects: 0
Study 23678500 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimizing waiting time between the three steps of the screening strategy.
Number of subjects: 0
Study 20102428 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based psychosocial intervention
Number of subjects: 325
Study 19021282 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 208
Study 19021282 — intervention group
Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 208
Study 17313873 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg daily for at least 52 weeks
Number of subjects: 519
Study 17313873 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LVD) 100 mg daily for at least 52 weeks
Number of subjects: 519
Study 17313873 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 519
Study 17313873 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (LVD)
Number of subjects: 519
Study 12822852 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 20
Study 12822852 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face
Number of subjects: 20
Study 10937502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 680
Study 10937502 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 680
Study 10937502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 680
Study 8590144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 3 x 600 mg bismuth subsalicylate and 2 x 1000 mg amoxycillin
Number of subjects: 113
Study 8590144 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate monotherapy
Number of subjects: 113
Study 8590144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured of H. pylori infection
Number of subjects: 113
Study 8590144 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive after treatment
Number of subjects: 113
Study 2665761 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decolonization (SDD) with non-resorbable antibiotics: 4 x 100 mg of polymyxin B, 4 x 500 mg of amphotericin B, and 4 x 80 mg of tobramycin via gastric tube.
Number of subjects: 102
Study 2665761 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decolonization (SDD) with non-resorbable antibiotics.
Number of subjects: 102
Study 2665761 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDD treatment).
Number of subjects: 102
Study 922398 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative reassurance about anaesthesia from a member of the hospital staff
Number of subjects: 0
Study 922398 — intervention group
Group type: COMPARATOR
Intervention: Reading a booklet designed to reassure about anaesthesia
Number of subjects: 0
Study 30967655 — intervention group
Group type: EXPERIMENTAL
Intervention: Early transpyloric feeding (TPF)
Number of subjects: 368
Study 30967655 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 368
Study 28917360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at LIV3
Number of subjects: 90
Study 28917360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at LI4
Number of subjects: 90
Study 28917360 — intervention group
Group type: COMPARATOR
Intervention: Placebo points
Number of subjects: 90
Study 28917360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (LIV3 or LI4)
Number of subjects: 90
Study 26337249 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in waist circumference (WC) over 6 years
Number of subjects: 2492
Study 26337249 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight women at baseline and ever-smokers
Number of subjects: 2492
Study 23527522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training during a 3-month meditation retreat
Number of subjects: 57
Study 21886949 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Body Resistance Training (UBRT) for 4 weeks, 3 times weekly
Number of subjects: 30
Study 21886949 — intervention group
Group type: COMPARATOR
Intervention: Breathing exercise for 10 min (Control Group)
Number of subjects: 30
Study 17687267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined muscarinic antagonist (glycopyrrolate, GLY) and alpha‐2 agonist (dexmedetomidine, DEX)
Number of subjects: 0
Study 17687267 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan (TMP)
Number of subjects: 0
Study 17687267 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 17023709 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based lunch meal fortified with 20 mg Fe as micronized ground ferric pyrophosphate (MGFP)
Number of subjects: 184
Study 17023709 — intervention group
Group type: COMPARATOR
Intervention: Control meal (unfortified rice-based lunch)
Number of subjects: 184
Study 14750577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day for 16 weeks)
Number of subjects: 815
Study 14750577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 14750577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 815
Study 14750577 — intervention group
Group type: EXPERIMENTAL
Intervention: None (TB monitoring)
Number of subjects: 815
Study 11279319 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 48
Study 11279319 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (1 month follow-up)
Number of subjects: 48
Study 11279319 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (6 months follow-up)
Number of subjects: 48
Study 11279319 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study 9499603 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital imaging and teledermatology
Number of subjects: 0
Study 8232372 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation with warfarin
Number of subjects: 0
Study 8232372 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet inhibitor therapy with aspirin
Number of subjects: 0
Study 8232372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3080292 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms qid
Number of subjects: 229
Study 3080292 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 300 micrograms qid
Number of subjects: 229
Study 3080292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 31121365 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (HsCRP) on day 3
Number of subjects: 90
Study 31121365 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (HsCRP) on day 8
Number of subjects: 90
Study 31121365 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐6, vascular cell adhesion molecule‐1, intercellular adhesion molecule‐1, interleukin‐8, interleukin‐10, interferon gamma, and tumor necrosis factor alpha
Number of subjects: 90
Study 29027598 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m2 plus pelareorep 3 × 10^10 TCID50
Number of subjects: 74
Study 29027598 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 74
Study 26741286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration (40 IU)
Number of subjects: 77
Study 26741286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 25421781 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered physical activity intervention (pedometers and eight weekly phone calls)
Number of subjects: 22
Study 25421781 — intervention group
Group type: COMPARATOR
Intervention: Control group (written information regarding physical activity)
Number of subjects: 22
Study 25421781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 23020794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54519
Study 20616686 — intervention group
Group type: EXPERIMENTAL
Intervention: 350-microg dexamethasone DDS
Number of subjects: 80
Study 20616686 — intervention group
Group type: EXPERIMENTAL
Intervention: 700-microg dexamethasone DDS
Number of subjects: 80
Study 20616686 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 80
Study 18823000 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, self-guided alcohol treatment program
Number of subjects: 44
Study 18823000 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study 15691345 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice
Number of subjects: 79
Study 15691345 — intervention group
Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 79
Study 15691345 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-brushing (with dentifrice)
Number of subjects: 79
Study 15691345 — intervention group
Group type: COMPARATOR
Intervention: Professional brushing (with dentifrice)
Number of subjects: 79
Study 15691345 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (self-brushing) vestibular surfaces
Number of subjects: 79
Study 15691345 — intervention group
Group type: COMPARATOR
Intervention: Brushing with dentifrice (professional brushing) vestibular surfaces
Number of subjects: 79
Study 11888048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-managed minimal-contact smoking cessation intervention
Number of subjects: 388
Study 11888048 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 388
Study 10765007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (INT)
Number of subjects: 153
Study 10765007 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (STD)
Number of subjects: 153
Study 7568598 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative prenatal program
Number of subjects: 116
Study 7568598 — intervention group
Group type: COMPARATOR
Intervention: Traditional prenatal education program
Number of subjects: 116
Study 1892240 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography
Number of subjects: 0
Study 1892240 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Doppler echocardiography
Number of subjects: 0
Study 6881256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integrative activities
Number of subjects: 7
Study 6881256 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activities (Control)
Number of subjects: 7
Study 31289018 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-OFDI guidance
Number of subjects: 106
Study 31289018 — intervention group
Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 106
Study 31240870 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5-minute rTMS protocol
Number of subjects: 30
Study 31240870 — intervention group
Group type: COMPARATOR
Intervention: 18.75-minute rTMS protocol
Number of subjects: 30
Study 30076982 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard advice plus personalised air-quality feedback (Group B)
Number of subjects: 120
Study 30076982 — intervention group
Group type: COMPARATOR
Intervention: Standard health service advice on SHS (Group A)
Number of subjects: 120
Study 27136447 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and acupuncture combined therapy
Number of subjects: 0
Study 27136447 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0
Study 25174484 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 U batroxobin
Number of subjects: 240
Study 25174484 — intervention group
Group type: COMPARATOR
Intervention: 50 mg mannitol
Number of subjects: 240
Study 21915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory conditioned stimulus (CS) presented nonreinforced
Number of subjects: 0
Study 21915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory conditioned stimulus (CS) presented extended
Number of subjects: 0
Study 21915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent presentations of the inhibitory CS with a novel CS
Number of subjects: 0
Study 19952822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg x kg(−1) caffeine
Number of subjects: 10
Study 19952822 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg x kg(−1) caffeine
Number of subjects: 10
Study 19952822 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg x kg(−1) caffeine
Number of subjects: 10
Study 19952822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18164275 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable lighting conditions (500-1800 lx, 6500 K; 500 lx, 4000 K)
Number of subjects: 0
Study 18164275 — intervention group
Group type: COMPARATOR
Intervention: Regular light
Number of subjects: 0
Study 18164275 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable light
Number of subjects: 0
Study 16485864 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty Index based on Comprehensive Geriatric Assessment (FI-CGA)
Number of subjects: 2305
Study 12017516 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific ADL observations
Number of subjects: 106
Study 12017516 — intervention group
Group type: COMPARATOR
Intervention: Barthel ADL Index
Number of subjects: 106
Study 9920950 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy (45 Gy over three weeks)
Number of subjects: 417
Study 9920950 — intervention group
Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy (45 Gy over five weeks)
Number of subjects: 417
Study 9920950 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily thoracic radiotherapy
Number of subjects: 417
Study 9920950 — intervention group
Group type: COMPARATOR
Intervention: Once-daily thoracic radiotherapy
Number of subjects: 417
Study 7731455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of 5-fluorouracil (500mg per day) for 14 days from 21 postoperative days and lipiodol-aclarubicin (40mg) at 35 POD
Number of subjects: 55
Study 7731455 — intervention group
Group type: COMPARATOR
Intervention: Control group (hepatectomy alone)
Number of subjects: 55
Study 7731455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of 5-fluorouracil and lipiodol-aclarubicin
Number of subjects: 55
Study 1665176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril-Hydrochlorothiazide 20 mg/12.5 mg
Number of subjects: 603
Study 1665176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril-Hydrochlorothiazide 20 mg/25 mg
Number of subjects: 603
Study 1665176 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 603
Study 1665176 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 603
Study 7378250 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline infusion intravenously at different rates
Number of subjects: 0
Study 31462252 — intervention group
Group type: EXPERIMENTAL
Intervention: Large plate
Number of subjects: 134
Study 31462252 — intervention group
Group type: COMPARATOR
Intervention: Small plate
Number of subjects: 134
Study 28077507 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105
Study 26193882 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physical activity on prescription (PAP) for 6 months
Number of subjects: 101
Study 26193882 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 23609927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured intervention (6 sessions)
Number of subjects: 131
Study 23609927 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 22909927 — intervention group
Group type: EXPERIMENTAL
Intervention: Religion-based tobacco control intervention (pamphlet describing health effects and rabbinical prohibitions on smoking)
Number of subjects: 340
Study 22909927 — intervention group
Group type: COMPARATOR
Intervention: Control group (schools without enforced smoking regulations)
Number of subjects: 340
Study 20212249 — intervention group
Group type: EXPERIMENTAL
Intervention: DD 9 microg/kg/d
Number of subjects: 144
Study 20212249 — intervention group
Group type: EXPERIMENTAL
Intervention: DD 18 microg/kg/d
Number of subjects: 144
Study 20212249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 20212249 — intervention group
Group type: EXPERIMENTAL
Intervention: DD (both doses)
Number of subjects: 144
Study 18035198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20, 40, and 80 mg daily)
Number of subjects: 7043
Study 18035198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 7043
Study 15727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Altoderm lotion (4% sodium cromoglicate)
Number of subjects: 114
Study 15727648 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 114
Study 15727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Altoderm lotion
Number of subjects: 114
Study 12243916 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (n=419) with accelerated alteplase
Number of subjects: 840
Study 9840118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (500 mg or 750 mg daily for 6 months)
Number of subjects: 150
Study 9840118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8302553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein solution (5 microliters) administered under the upper lid
Number of subjects: 2
Study 8302553 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein solution (5 microliters) administered under the lower lid
Number of subjects: 2
Study 2454783 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program consisting of 11 sessions over a 3-month period.
Number of subjects: 82
Study 2454783 — intervention group
Group type: COMPARATOR
Intervention: Low-birthweight (LBW) control group (no intervention).
Number of subjects: 82
Study 2454783 — intervention group
Group type: COMPARATOR
Intervention: Normal birthweight (NBW) control group (no intervention).
Number of subjects: 82
Study 2454783 — intervention group
Group type: EXPERIMENTAL
Intervention: LBW experimental group (early intervention).
Number of subjects: 82
Study 29189044 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (25-50 mg/d)
Number of subjects: 339
Study 29189044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 339
Study 29189044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 27535313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Awareness and Practice Scale (SHAPS)
Number of subjects: 194
Study 24761877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycididazole sodium (CMNa) 800 mg/m2 before radiotherapy, administered by intravenous drip, three times a week
Number of subjects: 91
Study 24761877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycididazole sodium (CMNa)
Number of subjects: 91
Study 23749007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision (UC)
Number of subjects: 40
Study 23749007 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 40
Study 19755476 — intervention group
Group type: EXPERIMENTAL
Intervention: PU- dialysis membrane
Number of subjects: 8
Study 19755476 — intervention group
Group type: EXPERIMENTAL
Intervention: PU+ dialysis membrane
Number of subjects: 8
Study 19755476 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Number of subjects: 8
Study 19755476 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis
Number of subjects: 8
Study 19755476 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with PU+
Number of subjects: 8
Study 18980082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral balloon valvuloplasty (MBV)
Number of subjects: 531
Study 16184835 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicose veins wall
Number of subjects: 26
Study 14513923 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (abstinent)
Number of subjects: 0